WHY SOME ONCOLOGY DOCTORS PREFER PRECISION MEDICINE FOR RARE CANCERS

Precision medicine is changing how oncology doctors treat rare cancers Hernia​. Unlike traditional chemotherapy, which attacks all rapidly dividing cells, precision medicine targets specific genetic mutations driving the cancer. This approach often leads to fewer side effects and better outcomes for patients with uncommon tumors. Oncologists who specialize in rare cancers increasingly rely on it because standard treatments frequently fail.

Rare cancers account for about 25% of all cancer diagnoses but receive far less research funding than common cancers like breast or lung cancer. This lack of attention means fewer approved treatments and limited clinical trial options. Precision medicine helps bridge this gap by identifying actionable genetic changes that may respond to existing targeted therapies, even if those drugs weren’t originally developed for that specific cancer type.

WHAT IS PRECISION MEDICINE IN ONCOLOGY?

Precision medicine in oncology uses genetic testing to match patients with treatments tailored to their tumor’s unique molecular profile. Instead of treating all cancers of the same type the same way, doctors analyze DNA, RNA, and proteins to find weaknesses in the cancer cells. Drugs like tyrosine kinase inhibitors or immunotherapy agents are then selected based on these findings.

For example, a patient with a rare sarcoma might have a mutation typically seen in lung cancer. If a drug exists for that mutation, the oncologist can prescribe it off-label. This approach is especially valuable for rare cancers, where large-scale clinical trials are rare, and standard treatment guidelines may not exist. Precision medicine turns a one-size-fits-all problem into a personalized solution.

WHY DO ONCOLOGISTS PREFER PRECISION MEDICINE FOR RARE CANCERS?

Oncologists prefer precision medicine for rare cancers because it offers hope where traditional treatments often fail. Many rare cancers don’t respond well to chemotherapy, and survival rates are lower than for common cancers. Precision medicine provides a way to outsmart the cancer by targeting its specific vulnerabilities, even if the cancer itself is poorly understood.

Another reason is the growing availability of genomic testing. Next-generation sequencing (NGS) can analyze hundreds of genes at once, revealing mutations that might be targetable. Oncologists no longer have to guess which treatment might work—they can make data-driven decisions. This is particularly important for rare cancers, where every patient’s tumor may behave differently.

HOW DOES PRECISION MEDICINE WORK IN PRACTICE?

Precision medicine starts with a biopsy of the tumor, which is then sent for genomic testing. The lab sequences the DNA to identify mutations, fusions, or other alterations. The oncologist reviews the results to see if any of the changes match approved or investigational therapies. If a match is found, the patient may receive a targeted drug, often in combination with other treatments.

For instance, a patient with a rare bile duct cancer might have an FGFR2 fusion. The oncologist could prescribe pemigatinib, a drug approved for this specific mutation. Without precision medicine, this patient might have received standard chemotherapy with little benefit. The process isn’t perfect—some mutations have no matching drugs—but it’s a significant improvement over trial-and-error treatment.

WHAT ARE THE LIMITATIONS OF PRECISION MEDICINE FOR RARE CANCERS?

Precision medicine isn’t a cure-all. One major limitation is that not all mutations are actionable. Some genetic changes have no targeted therapies, leaving patients with few options. Even when a drug exists, the cancer may develop resistance over time, requiring additional testing and treatment adjustments.

Another challenge is access. Genomic testing can be expensive, and insurance may not always cover it. Some patients live in areas without access to specialized labs or oncologists trained in precision medicine. Additionally, rare cancers often lack the robust data seen in common cancers, making it harder to predict which treatments will work. Despite these hurdles, precision medicine remains one of the best tools for treating rare cancers.

HOW DO PATIENTS ACCESS PRECISION MEDICINE?

Patients access precision medicine through their oncology team. The process begins with a discussion about genomic testing, which may be recommended if standard treatments aren’t effective. The oncologist orders the test, and the results are reviewed to identify potential targeted therapies. If a match is found, the doctor may prescribe the drug or refer the patient to a clinical trial.

Some patients seek second opinions at major cancer centers, where precision medicine programs are more advanced. Organizations like the National Cancer Institute (NCI) and the Rare Cancer Research Foundation also provide resources for finding specialized care. Patients should ask their oncologist about genomic testing early in their treatment journey, especially if their cancer is rare or aggressive.

WHAT ARE THE SUCCESS STORIES OF PRECISION MEDICINE IN RARE CANCERS?

Precision medicine has led to remarkable success stories in rare cancers. One example is the drug larotrectinib, which targets NTRK gene fusions. These fusions occur in less than 1% of all cancers but are found in several rare tumor types. Larotrectinib has shown high response rates in patients with these fusions, regardless of where the cancer originated.

Another success is the use of BRAF inhibitors in rare melanomas and other cancers with BRAF mutations. These drugs were originally developed for melanoma but have since been used off-label for other rare cancers with the same mutation. Stories like these highlight how precision medicine can turn a devastating diagnosis into a manageable condition, even for cancers that were once considered untreatable.

WHAT DOES THE FUTURE HOLD FOR PRECISION MEDICINE IN RARE CANCERS?

The future of precision medicine in rare cancers is promising. Advances in technology are making genomic testing faster, cheaper, and more accurate. Liquid biopsies, which analyze cancer DNA from a blood sample, are becoming more common, reducing the need for invasive tumor biopsies. Artificial intelligence is also being used to analyze complex genetic data, helping oncologists identify patterns that might otherwise be missed.

More targeted therapies are in development, including drugs for mutations that currently have no treatment options. Clinical trials are increasingly focusing on rare cancers, giving patients access to cutting-edge treatments. As precision medicine becomes more widespread, it has the potential to transform rare cancer care, offering hope to patients who previously had none.

WHY SHOULD PATIENTS WITH RARE CANCERS CONSIDER PRECISION MEDICINE?

Patients with rare cancers should consider precision medicine because it offers a personalized approach that standard treatments often can’t. Rare cancers are frequently misdiagnosed or treated with one-size-fits-all therapies that don’t work. Precision medicine provides a way to tailor treatment to the individual, increasing the chances of a positive outcome.

It also empowers patients to take an active role in their care. Genomic testing provides concrete information about the cancer, which can guide treatment decisions and open doors to clinical trials. For many patients, precision medicine is the difference between a grim prognosis and a fighting chance. The earlier it’s considered, the better the potential results.

HOW CAN PATIENTS ADVOCATE FOR PRECISION MEDICINE?

Patients can advocate for precision medicine by asking their oncologist about genomic testing. They should inquire whether their cancer has been tested for actionable mutations and if any targeted therapies are available. If the oncologist isn’t familiar with precision medicine, patients can seek a second opinion at a specialized cancer center.

Joining patient advocacy groups can also help. Organizations like the Rare Cancer Research Foundation and the NCI’s Rare Tumors Initiative provide resources and support for patients navigating rare cancers. Patients should also ask about clinical trials, as many precision medicine treatments are only available through research studies. Being proactive can make a significant difference in treatment options.

WHAT QUESTIONS SHOULD PATIENTS ASK THEIR ONCOLOGIST ABOUT PRECISION MEDICINE?

Patients should ask their oncologist if genomic testing has been done or is recommended for their cancer. They should inquire about the specific mutations found and whether any targeted therapies exist. Questions like, “Are there clinical trials for my mutation?” or “What are the potential side effects of targeted